Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) saw a significant increase of over 4%, currently trading at HKD 10.68 with a transaction volume of HKD 2.7829 million, following the announcement of its new drug clinical trial application acceptance by the National Medical Products Administration (NMPA) [1] Group 1: Company Developments - Corning Jereh announced that its self-developed PD-L1/VEGFR2 bispecific antibody drug conjugate (ADC) JSKN027 has received formal acceptance for clinical trial (IND) application by the NMPA [1] - The company is set to initiate Phase I clinical research for JSKN027, targeting advanced malignant solid tumors [1] - JSKN027 is the first PD-L1/VEGFR2 bispecific ADC to enter clinical research globally, with preclinical data showing significant tumor suppression activity in both in vitro and in vivo models [1] Group 2: Industry Context - Currently, there are no ADCs targeting VEGFR2 alone or simultaneously targeting both PD-L1 and VEGFR pathways in clinical research worldwide [1]
康宁杰瑞制药-B涨超4% 新药JSKN027临床试验申请获受理